Trials / Recruiting
RecruitingNCT07348055
A Study of GR1803 in Systemic Lupus Erythematosus
A Phase Ib/IIa Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of GR1803 Injection in Subjects With Systemic Lupus Erythematosus
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 44 (estimated)
- Sponsor
- Genrix (Shanghai) Biopharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
to evaluate the safety and efficacy of GR1803 in the treatment of patients with systemic lupus erythematosus
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | GR1803 injection | step-up dosing, Dose and frequency according to the protocol |
Timeline
- Start date
- 2026-02-02
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2026-01-16
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07348055. Inclusion in this directory is not an endorsement.